

R⁷ is independently selected from the group consisting of -H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and -C(O)R¹⁰;

R⁸ is independently selected from the group consisting of -H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, -C(O)R¹⁰, or together said R⁸ groups form a bidendate alkylene;

R⁹ is selected from the group consisting of alkyl, aralkyl, alicyclic, and heteroalicyclic;

R¹⁰ is selected from the group consisting of -H, lower alkyl, -NH₂, lower aryl, and lower perhaloalkyl;

R¹¹ is selected from the group consisting of alkyl, aryl, -OH, -NH₂ and -OR³; and pharmaceutically acceptable prodrugs and salts thereof.

In the Specification:

Please amend the specification as follows:

At page 1, line 2 (after the title of the invention), please insert:

--Related Applications

This application is a continuation application of U.S. Application Serial No. 09/944,096, filed August 30, 2001, which was a divisional application of U.S. Patent No. 6,284,748, dated September 4, 2001 (U.S. Application Serial No. 09/036,327, filed March 6, 1998) which claims benefit of and is a continuation-in-part of U. S. Provisional Application No. 60/040,623 filed March 7, 1997. --

Remarks


Support for the new claim can be found throughout the specification. For instance, p. 6 lines 17-20, 23-25 and p. 61, lines 15-24.

Therefore, no new matter is added as a result of these amendments.

The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Deposit Account No. 50-2613.

Respectfully submitted,

Dated: July 7, 2003



Diana L. Bush, Ph.D., Esq.

Reg. No. 51,109

PAUL, HASTINGS, JANOFSKY & WALKER LLP
12390 El Camino Real
San Diego, CA 92130-2081
Phone: (858) 720-2500
Fax: (858) 720-2555